Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease

JAMA

Volumn 294, Issue 23, 2005, Pages 2989-2995

  Dial, Sandra ^a,d   Delaney, J A C ^a,c   Barkun, Alan N ^b,c   Suissa, Samy ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BACTERIAL INFECTION; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; FEMALE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; PRIORITY JOURNAL; RISK ASSESSMENT; STOMACH ACID;

EID: 29144473282     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.294.23.2989     Document Type: Article

References (63)

1. Kyne L, Merry C, O'Connell B, Keane C, O'Neill D. Community-acquired Clostridium difficile infection. J Infect. 1998;36:287-288.
2. Karlstrom O, Fryklund B, Tullus K, Burman LG. A prospective nationwide study of Clostridium difficileassociated diarrhea in Sweden: the Swedish C. difficile Study Group. Clin Infect Dis. 1998;26:141-145.
3. Riley TV, Wymer V, Bamford VW, Bowman RA. Clostridium difficile in general practice and community health. J Hyg (Lond). 1986;96:13-17.
4. Wheeler JG, Sethi D, Cowden JM, et al. Study of infectious intestinal disease in England: rates in the community, presenting to general practice, and reported to national surveillance. BMJ. 1999;318:1046-1050.
5. National Clostridium difficile Standards Group. National Clostridium difficile Standards Group: report to the Department of Health. J Hosp Infect. 2004;56(suppl 1):1-38.
6. Beaugerie L, Flahault A, Barbut F, et al. Antibioticassociated diarrhoea and Clostridium difficile in the community. Aliment Pharmacol Ther. 2003;17:905-912.
7. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171:466-472.
8. Hirschhorn LR, Trnka Y, Onderdonk A, et al. Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis. 1994;169:127-133.
9. Noren T, Akerlund T, Back E, et al. Molecular epidemiology of hospital-associated and communityacquired Clostridium difficile infection in a Swedish county. J Clin Microbiol. 2004;42:3635-3643.
10. McFarland LV, Surawicz CM, Stamm WE. Risk factors for Clostridium difficile carriage and C. difficileassociated diarrhea in a cohort of hospitalized patients. J Infect Dis. 1990;162:678-684.
11. Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine. Gut. 1996;39:54-59.
12. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, et al. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med. 2002;30:1118-1122.
13. Yoshida N, Yoshikawa T, Tanaka Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors-inhibitory effects on neutrophilendothelial cell interactions. Aliment Pharmacol Ther. 2000;14(suppl 1):74-81.
14. Agastya G, West BC, Callahan JM. Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro. Immunopharmacol Immunotoxicol. 2000;22:357-372.
15. Laheij R, Sturkenboom MC, Hassing R, et al. Risk of commuity-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292:1955-1960.
16. Williams C. Occurrence and significance of gastric colonization during acid-inhibitory therapy. Best Pract Res Clin Gastroenterol. 2001;15:511-521.
17. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect. 2003;54:243-245.
18. Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and casecontrol studies. CMAJ. 2004;171:33-38.
19. Al Tureihi FI, Hassoun A, Wolf-Klein G, Isenberg H. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. J Am Med Dir Assoc. 2005;6:105-108.
20. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005;26:273-280.
21. Walley T, Mantgani A. The UK General Practice Research Database. Lancet. 1997;350:1097-1099.
22. Garcia Rodriguez LA, Perez GS. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998;45:419-425.
23. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based comput-erised data resource in the United Kingdom. BMJ. 1991;302:766-768.
24. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy. 2003;23:686-689.
25. Lawrenson R, Williams T, Farmer R. Clinical information for research; the use of general practice databases. J Public Health Med. 1999;21:299-304.
26. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med. 2002;136:834-844.
27. Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. In: Strom BL, ed. Pharmacoepidemiology. 3rd ed. West Sussex, England: John Wiley & Sons; 2000:785-805.
28. Itskowitz MS, Lebovitz PJ. Non-antibiotic associated pseudomembranous colitis: a case report and review of the literature. Adv Stud Med. 2003;3:571-574.
29. Cunney RJ, Magee C, McNamara E, Smyth EG, Walshe J. Clostridium difficile colitis associated with chronic renal failure. Nephrol Dial Transplant. 1998;13:2842-2846.
30. Meyer AM, Ramzan NN, Loftus EV Jr, Heigh RI, Leighton JA. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol. 2004;38:772-775.
31. Mylonaki M, Langmead L, Pantes A, et al. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol. 2004;16:775-778.
32. Wilson KH, Sheagren JN, Freter R. Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian hampster. J Infect Dis. 1985;151:355-361.
33. Klingensmith ME, Neville LJ, Delpire E, WolfeMM, Soybel DI. Gastrin-mediated effects of omeprazole on rat colon mucosa. Surgery. 1999;126:272-278.
34. West BC, Agastya G, Sodeman W, Callahan J. Furunculosis associated with repeated courses of omeprazole therapy. Clin Infect Dis. 1998;26:1234-1235.
35. Shah S, Lewis A, Leopold D, et al. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM. 2000;93:175-181.
36. Pepin J, Saheb N, Coulombe M, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254-1260.
37. Health Protection Agency. Reports of Clostridium difficile isolated from faecal specimens under the voluntary reporting scheme: England, Wales, and Northern Ireland 1990-2004. Health Protection Agency UK Web site. Available at: http:// www.hpa.org.uk/infections/topics_az/clostridium _difficile/vol_data.htm. Accessed October 7, 2005.
38. Barrett S. Clostridium difficile-the next step in mandatory reporting. J Hosp Infect. 2004;56:83-84.
39. Wilcox MH. Gastrointestinal disorders and the critically ill: Clostridium difficile infection and pseudomembranous colitis. Best Pract Res Clin Gastroenterol. 2003;17:475-493.
40. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis. 1998;26:1027-1034.
41. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect. 1998;40:1-15.
42. Johnson S, Clabots CR, Linn FV, et al. Nosocomial Clostridium difficile colonisation and disease. Lancet. 1990;336:97-100.
43. Gerding DN, Olson MM, Peterson LR, et al. Clostridium difficile-associated diarrhea and colitis in adults: a prospective case-controlled epidemiologic study. Arch Intern Med. 1986;146:95-100.
44. Simor AE, Yake SL, Tsimidis K. Infection due to Clostridium difficile among elderly residents of a longterm-care facility. Clin Infect Dis. 1993;17:672-678.
45. Wilcox MH, Bendall R, Settle CD, Fawley WN. Community Clostridium difficile infection. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2001; Chicago, Ill. Abstract 441.
46. Falsen E, Kaijser B, Nehls L, Nygren B, Svedhem A. Clostridium difficile in relation to enteric bacterial pathogens. J Clin Microbiol. 1980;12:297-300.
47. Barbut F, Decre D, Lalande V, et al. Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. J Med Microbiol. 2005;54:181-185.
48. Gentric A, Pennec YL. Diclofenac-induced pseudomembranous colitis. Lancet. 1992;340:126-127.
49. Romero-Gomez M, Suarez GE, Castro FM. Pseudomembranous colitis induced by diclofenac. J Clin Gastroenterol. 1998;26:228.
50. Moskovitz M, Bartlett JG. Recurrent pseudomembranous colitis unassociated with prior antibiotic therapy. Arch Intern Med. 1981;141:663-664.
51. Robert A, Bundy GL, Field SO, et al. Prevention of cecitis in hamsters by certain prostaglandins. Prostaglandins. 1985;29:961-980.
52. Ruwart MJ, Renis HE, Erlandson AL, et al. 16,16-dimethyl-prostaglandin E2 inhibits toxin release from Clostridium difficile. Adv Prostaglandin Thromboxane Leukot Res. 1983;12:93-98.
53. Copeland KT, Checkoway H, McMichael AJ, Holbrook RH. Bias due to misclassification in the estimation of relative risk. Am J Epidemiol. 1977;105:488-495.
54. Price AB. Pathology of drug-associated gastrointestinal disease. Br J Clin Pharmacol. 2003;56:477-482.
55. Wilton LV, Key C, Shakir SA. The pharmacovigilance of pantoprazole: the results of postmarketing surveillance on 11 541 patients in England. Drug Saf. 2003;26:121-132.
56. Vial T, Goubier C, Bergeret A, et al. Side effects of ranitidine. Drug Saf. 1991;6:94-117.
57. Spigaglia P, Mastrantonio P. Comparative analysis of Clostridium difficile clinical isolates belonging to different genetic lineages and time periods. J Med Microbiol. 2004;53:1129-1136.
58. Geric B, Rupnik M, Gerding DN, Grabnar M, Johnson S. Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital.J Med Microbiol. 2004;53:887-894.
59. McEllistrem MC, Carman RJ, Gerding DN, et al. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis. 2005;40:265-272.
60. Pepin J, Valiquette L, Cossette B. Mortality attributable to nosocomial Clostridium difficileassociated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ. 2005;173:1037-1042.
61. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366:1079-1084.
62. McDonald LC, Killgore GE, Thompson A, Johnson S, Gerding DN; and the Clostridium difficile Investigation Team. Emergence of an epidemic strain of Clostridium difficile in the United States, 2001-4: potential role for virulence factors and antimicrobial resistance traits. Presented at Infectious Diseases Society of America 42nd Annual Meeting; September 30-October 3, 2004; Boston, Mass. Abstract LB-2.
63. IMS Health National Sales Perspectives Web site. 2004 Year-End US Prescription and Sales Information and Commentary. Available at: http://www.imshealthcanada.com/htmen/3_2_28.htm. Accessed November 21, 2005.